Inge M.W. Verberk

Mar 1, 2024 | nature.com | Joseph Therriault |Suzanne Schindler |Gemma Salvadó |Thomas K. Karikari |Melissa Murray |Inge M.W. Verberk | +5 more

AbstractDisease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. Current in vivo diagnostic frameworks for AD are based on abnormal concentrations of amyloid-β and tau in the cerebrospinal fluid or on PET scans, and breakthroughs in molecular imaging have opened up the possibility of in vivo staging of AD.

Oct 27, 2023 | science.org | Inge M.W. Verberk |Jackie Oberst

Register NOWRemaining time: 7 DAYS | 22 HRS | 02 MINS Inge Verberk, Ph.D.Speaker Jackie Oberst, Ph.D.Moderator Phosphorylated tau (p-Tau), amyloid-beta (Ab) 42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are current key Alzheimer’s disease (AD) blood-based biomarkers. Interpreting results of the four biomarkers simultaneously in a clinical context is challenging due to issues such as tissue sample size, cost, and timing. A decision algorithm could aid in the...